New Delhi: One of Covid-19 vaccine manufacturers in India, Bharat Biotech, has reportedly sought DCGI’s permission to extend the shelf-life of its indigenously developed vaccine ‘Covaxin’ from six to 24 months, as per sources revealed on Sunday.
‘Covaxin’, along with ‘Covishield’ ( manufactured by Serum Institute of India) – are the two vaccines so far being used in India’s current COVID-19 vaccination drive. Russian vaccine ‘Sputnik-V’ has also been approved for emergency use in India.
Notably, the Hyderabad-based Bharat Biotech was given permission for sale and distribution of Covaxin with shelf life of six months when stored at two to eight degrees Celsius.
“Now, we are herewith applying for the extension of shelf life from six months to 24 months when stored at 2-8 degrees Celsius,” the firm said in its application to the Drugs Controller General of India.
In support of their proposal, Bharat Biotech has submitted updated accelerated and real-time stability data of ‘Covaxin’ along with the justification for the extension of shelf-life.
It is to be mentioned that the DCGI had extended the shelf-life of Covishield from six to nine months from its manufacturing date in February.